Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Does obesity affect treatment response to secukinumab and its survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry
Mod Rheumatol.2023 doi 10.1093/mr/road061 Epub ahead of print
This observational study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.
Keywords:
Factors Associated with the Retention of Secukinumab in Patients with Axial Spondyloarthritis in Real-world Practice: Results from a Retrospective Study (FORSYA)
RMD Open. 2023 doi: 10.1136/rmdopen-2022-002802 Epub Ahead of Print
This study reported the overall retention of secukinumab in daily practice in the period following its approval in France was approximately 59% at 1 year in axSpA patients. The aim of this study was to determine whether OSI were predictive of secukinumab retention at 1 year.
Keywords:
Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-responder and Secondary Non-responder of Prior TNF Inhibitor in Ankylosing Spondylitis
Mod Rheumatol. 2023 doi: 10.1093/mr/roac005
This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.
Keywords:
Real-world Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results from the CanSpA Research Network
J Rheumatol. 2023 jrheum doi: 10.3899/jrheum.220824
The results of this real-world study of Canadian axSpA patients, the first of its kind, support the effectiveness of secukinumab for treatment of axSpA. This study aimed to use the CanSpA Research Network to describe real-world retention and effectiveness of secukinumab in the Canadian axSpA population.
Keywords:
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586
Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac285
Real-world population-based study shows that a switch to a second JAKinib results in a higher drug retention, as compared to switching to a TNFi, in patients with RA who discontinue original JAKinib therapy.
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068
Data from the Swedish Rheumatology Quality Register and Swedish Registries, show a higher treatment retention and overall equivalent or better treatment response on baricitinib, compared with bDMARDs or tofacitinib, but no statistically significant differences between tofacitinib and bDMARDs.In this largest population-based study to date, comparing RA patients initiating baricitinib, tofacitinib or bDMARDs, Barbulescu, et al. help to fill some of the current knowledge gaps surrounding the effica...Keywords:
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Arthritis Res Ther 2020;22:142
This paper is based upon a long-term cohort study, namely the ANSWER cohort, an observational multi-centre registry of RA patients in the Kansai district of Japan. Analyses demonstrate a difference in observed drug retention between bDMARDs-naïve and bDMARDs-switched patients. 7 bDMARD treatments were compared in patients with no prior exposure to biologics, with abatacept showing the greatest retention rate. In patients that had switched between these same bDMARDs or to tofacitinib throughout t...
Long-term Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis, Stratified by Number of Previous Treatment Failures with Biologic Agents: Results from the German RABBIT Cohort
Rheumatol Int 2018 Apr; 38(4):579-87
In this observational study, the German RABBIT cohort was used to assess the long-term effectiveness and retention rates of tocilizumab (TCZ) in patients with prior bDMARD failures. Results of the study suggested that TCZ could be an effective treatment option for patients with difficult-to-treat RA. A total of 885 patients were involved in the study and these were categorised dependent on the number of bDMARD failures they had prior to TCZ treatment. Patient data recorded in the cohort included...
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Ann Rheum Dis. 2015 Sep 15. doi:10.1136/ annrheumdis-2015-207760
Biological DMARDs have markedly changed the management and outcome of rheumatoid arthritis. Most international guidelines recommend the use of biological DMARDs in combination with MTX or other synthetic DMARDs (sDMARDs) (where MTX is not tolerated or contraindicated), based primarily on the observation that MTX enhances the efficacy of TNF antagonists in both clinical trials and observational studies.This study examined the effectiveness of tocilizumab (TCZ), an anti-IL-6 monoclonal antibody, ...